What changed in Beone Medicines Ltd.'s latest annual report
In the year ended 31 Dec 2025, Beone Medicines Ltd.'s revenue rose 40.2% to USD 5.34bn, from USD 3.81bn; long-term debt rose 477.8% to USD 961.91m, from USD 166.48m; cash and cash equivalents rose 73.1% to USD 4.55bn, from USD 2.63bn.
Year ended 31 Dec 2025. Source: 10-K filed 26 Feb 2026, read it on SEC EDGAR.
USD 3.81bn to USD 5.34bn
The figures, year on year
| Item | Year before | Latest year | Change |
|---|---|---|---|
| Revenue | 3.81bn | 5.34bn | Up 40.2% |
| Net income | -644.79m | 286.93m | Not comparable |
| Total assets | 5.92bn | 8.19bn | Up 38.3% |
| Total liabilities | 2.59bn | 3.83bn | Up 47.9% |
| Long-term debt | 166.48m | 961.91m | Up 477.8% |
| Cash and cash equivalents | 2.63bn | 4.55bn | Up 73.1% |
| Shareholders' equity | 3.33bn | 4.36bn | Up 30.9% |
Questions people ask
Did Beone Medicines Ltd.'s revenue grow last year?
Revenue grew 40.2%, from USD 3.81bn to USD 5.34bn in the year ended 31 Dec 2025.
Is Beone Medicines Ltd. profitable?
Yes. Net income was USD 286.93m in the year ended 31 Dec 2025. The year before: a net loss of USD 644.79m.
How much cash and debt does Beone Medicines Ltd. have?
At its latest year end (31 Dec 2025), Beone Medicines Ltd. reported cash and cash equivalents of USD 4.55bn and long-term debt of USD 961.91m.
Where do these numbers come from?
From Beone Medicines Ltd.'s own annual filings with the SEC. Each change is calculated from the reported figures; nothing is estimated.
Meeting a client who works with Beone Medicines Ltd.?
LYNORIQ remembers every client meeting the way this page tracks a filing: what changed since last time, what you promised, and what they owe you.
Start free See the demoOther Pharmaceutical Preparations companies
- Eli Lilly And CompanyCash and cash equivalents up 122.4%
- Johnson & JohnsonNet income up 90.6%
- AbbVie Inc.Revenue up 8.6%
- Merck & Co., Inc.Long-term debt up 35.7%
- Abbott LaboratoriesNet income down 51.3%
- Pfizer IncCash and cash equivalents up 9.5%
- Vertex Pharmaceuticals Inc / MaTotal liabilities up 13.9%
- Bristol-Myers Squibb CompanyShareholders' equity up 13.1%